1
|
Noël J, Stirt D, Moschovas MC, Reddy S, Jaber AR, Sandri M, Bhat S, Rogers T, Ahmed S, Mascarenhas A, Patel E, Patel V. Oncologic outcomes with and without amniotic membranes in robotic-assisted radical prostatectomy: A propensity score matched analysis. Asian J Urol 2024; 11:19-25. [PMID: 38312822 PMCID: PMC10837667 DOI: 10.1016/j.ajur.2022.05.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2022] [Accepted: 05/20/2022] [Indexed: 10/17/2022] Open
Abstract
Objective Placement of human placenta derived grafts during robotic-assisted radical prostatectomy (RARP) hastens the return of continence and potency. The long-term impact on the oncologic outcomes remains to be investigated. Our objective was to determine the oncologic outcomes of patients with dehydrated human amnion chorion membrane (dHACM) at RARP compared to a matched cohort. Methods In a referral centre, from August 2013 to October 2019, 599 patients used dHACM in bilateral nerve-sparing RARP. We excluded patients with less than 12 months follow-up, simple prostatectomy, and unilateral nerve-sparing. Patients with dHACM (amnio group) were 529, and were propensity score matched 1:1 to 2465 patients without dHACM (non-amnio group) and a minimum follow-up of 36 months. At the time of RARP, dHACM was placed around the neurovascular bundle in the amnio group. Continuous and categorical variables in matched groups was tested by two-sample Kolmogorov-Smirnov test and Fisher's exact test respectively. Outcomes measured were biochemical recurrence (BCR), adjuvant and salvage therapy rates. Results Propensity score matching resulted in two groups of 444 patients. Cumulative incidence functions for BCR did not show a difference between the groups (p=0.3). Patients in the non-amnio group required salvage therapy more frequently than the amnio group, particularly after partial nerve-sparing RARP (6.3% vs. 2.3%, p=0.001). Limitations are the absence of prospective randomization. Conclusion The data suggest that using dHACM does not have a negative impact on BCR in patients. Outcomes of cancer specific and overall survival will require follow-up study to increase our understanding of these grafts' impact on prostate cancer biology.
Collapse
Affiliation(s)
- Jonathan Noël
- Advent Health Global Robotics Institute, Celebration, FL, USA
| | - Daniel Stirt
- University of Central Florida College of Medicine, Orlando, FL, USA
| | - Marcio Covas Moschovas
- Advent Health Global Robotics Institute, Celebration, FL, USA
- University of Central Florida College of Medicine, Orlando, FL, USA
| | - Sunil Reddy
- Advent Health Global Robotics Institute, Celebration, FL, USA
| | | | - Marco Sandri
- Big and Open Data Innovation Laboratory, University of Brescia, Italy
| | | | - Travis Rogers
- Advent Health Global Robotics Institute, Celebration, FL, USA
| | - Subuhee Ahmed
- Kansas City University College of Medicine, Kansas City, MO, USA
| | | | - Ela Patel
- Advent Health Global Robotics Institute, Celebration, FL, USA
| | - Vipul Patel
- Advent Health Global Robotics Institute, Celebration, FL, USA
- University of Central Florida College of Medicine, Orlando, FL, USA
| |
Collapse
|
2
|
Saag JL, Gross D, Stirt D, Espina Rey A, Gros B. Role of Different Low-Density Lipoprotein-Lowering Medications on Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients With Diabetes Mellitus. Cureus 2023; 15:e40905. [PMID: 37492827 PMCID: PMC10365890 DOI: 10.7759/cureus.40905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Accepted: 06/22/2023] [Indexed: 07/27/2023] Open
Abstract
Purpose The objective of this study was to explore the optimal cholesterol-lowering therapy for diabetic patients categorized as having a very high risk for future atherosclerotic cardiovascular disease (ASCVD) events. The primary medications under investigation were statins, ezetimibe, and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors (PCSK9-Is). The efficacy of different medication regimens helped to draw conclusions regarding the evolution of cholesterol management recommended under the American College of Cardiology's (ACC) 2013 and 2018 guidelines. Methods A retrospective chart review was conducted on a cohort of patients from a large, community-based cardiology practice. Inclusion criteria specified patients aged 30-82 with a past medical history of two or more ASCVD events or one ASCVD event and at least two high-risk comorbidities. Acquired data included demographics, all lipid panels, medications used, and ASCVD events between December 1, 2013, and December 31, 2019. The data were stored and encrypted on a REDCap account. Sub-group analysis was conducted on only diabetic patients, who were then categorized by medication regimen. The statistical analysis was completed using Fisher's exact test. A p-value <0.05 was considered significant. Results A total of 102 diabetic patients met the inclusion criteria. Our primary analysis determined the percentage of patients who achieved their goals on each medication regimen. The goal was defined as a low-density lipoprotein cholesterol (LDL-C) level of less than 70 mg/dL or at least a 50% reduction from baseline levels. The results are as follows: none (0%), statin (33.9%), ezetimibe (21.1%), statin + ezetimibe (73.5%), PCSK9-Is ± statin (83.3%), and PCSK9-Is and ezetimibe ± statin (100%). There proved to be a significant difference favoring all combination regimens over statins alone; however, there was no significant difference between these advanced regimens. A follow-up analysis determined if these patients were able to maintain their goals in the subsequent lipid panel after achieving their goals. The results are as follows: none (0%), statin (61.5%), ezetimibe (50%), statin + ezetimibe (77.8%), PCSK9-Is ± statin (100%), and PCSK9-Is and ezetimibe ± statin (66.6%). The only significant difference found was between PCSK9-Is ± statins and statins alone. Conclusions Our study revealed that regimens using PCSK9 inhibitors and ezetimibe, in addition to maximally tolerated statin therapy, were more effective than statin therapy alone in achieving the goal. On extended analysis, only PCSK9 inhibitors showed superior ability in terms of maintaining the goals for diabetic patients at very high risk for future ASCVD events. This implies that statins alone may be inadequate to properly treat this specific patient population. In the context of clinical practice, physicians could have heightened consideration for dual therapy consisting of maximally tolerated statins and a secondary agent in accordance with the 2018 ACC guidelines.
Collapse
Affiliation(s)
- Jordan L Saag
- Medical School, University of Central Florida College of Medicine, Orlando, USA
| | - Dennis Gross
- Medical School, University of Central Florida College of Medicine, Orlando, USA
| | - Daniel Stirt
- Medical School, University of Central Florida College of Medicine, Orlando, USA
| | - Andrea Espina Rey
- Epidemiology and Public Health, University of Central Florida College of Medicine, Orlando, USA
| | - Bernard Gros
- Internal Medicine, University of Central Florida College of Medicine, Orlando, USA
| |
Collapse
|
3
|
Reddy S, Noel J, Moschovas M, Bhat KRS, Perera R, Rogers TP, Stirt D, Doss J, Jenson C, Andrich J, Patel V. Same Day Discharge Protocol for Robotic Assisted Radical Prostatectomy: the experience of a High-Volume Referral Center. J Endourol 2022; 36:934-940. [PMID: 35166120 DOI: 10.1089/end.2021.0730] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Objective As the COVID-19 global pandemic continues, there is increased value in performing same-day discharge (SDD) protocols to minimize viral exposure and maintain the appropriate surgical treatment for oncological patients. In this scenario, we performed a prospective analysis of outcomes of our patients undergoing SDD protocol after robotic-assisted radical prostatectomy (RARP). Material and Methods The SDD criteria included patients with no intraoperative complications, stable postoperative hemoglobin levels (compared to preoperative values), stable vital signs, normal urine output, ambulation with assistance and independently without dizziness, tolerance of clear liquids without nausea or vomiting, pain control with oral medication, and patient/family confidence with SDD. Patients older than 70 years, concomitant general surgery operations, multiple comorbidities, and complex procedures such as salvage surgery were excluded from our protocol. Results Of the 101 patients who met the criteria for SDD, 73 (72%) had a successful SDD. All SDF (Same day discharge failure) patients were discharged one day after surgery. Intraoperative characteristics were not statistically different with a median operative time of 92 (81-107) vs 103 (91-111) minutes for SDD and SDF respectively. Of the 28 SDF patients, the most common reasons for staying were anesthesia-related factors of nausea (35%), drowsiness (7%), patient/caregiver preference (25%), pain (14%), labile blood pressure (7%), arrhythmia (7%), and dizziness (7%). There was no significant difference in readmission rates, complication rates, or post-operative pain scores between SDD and SDF patients. Conclusions In our experience, SDD for patients undergoing RARP can be safely and feasibly incorporated into a clinical care pathway without increasing readmission rates. We were successful in 72% of cases due to coordinated care between anesthetics, nursing staff, and appropriate patient selection. We also believe that incorporating pre-and postoperative patient education and assurance is crucial to minimize their exposure to COVID-19 during the surgical treatment for prostate cancer.
Collapse
Affiliation(s)
- Sunil Reddy
- Global Robotic Institute, Urology, Celebration, Florida, United States;
| | - Jonathan Noel
- AdventHealth Global Robotics Institute, Urology, Celebration, Florida, United States;
| | - Marcio Moschovas
- AdventHealth, 6245, Urology, Celebration, Florida, United States;
| | - Kulthe Ramesh Seetharam Bhat
- AdventHealth Global Robotics Institute, Urology, 400 Celebration place, suite 200, celebration, Florida, United States, 34747.,Global robotics institute;
| | - Roshane Perera
- University of Florida, 3463, Gainesville, Florida, United States;
| | - Travis Phillip Rogers
- Florida Hospital Celebration Health, 23067, 410 Celebration Pl, Celebration, Florida, United States, 34747-4970.,United States;
| | - Daniel Stirt
- University of Central Florida, 6243, Medicine, Orlando, Florida, United States;
| | - Janice Doss
- Adventhealth Global Robotics Institute, Florida, United States;
| | - Cathy Jenson
- Florida Hospital Celebration Health, 23067, 410 Celebration p, Suite 200, Celebration, Florida, United States, 34747;
| | - John Andrich
- Adventhealth Global Robotics Institute, Florida, United States;
| | - Vipul Patel
- AdventHealth Global Robotics Institute, Urology, Celebration, Florida, United States;
| |
Collapse
|
4
|
Patel E, Mascarenhas A, Ahmed S, Stirt D, Brady I, Perera R, Noël J. Evaluating the ability of students to learn and utilize a novel telepresence platform, proximie. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)02314-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|